[
  {
    "ts": null,
    "headline": "Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer",
    "summary": "IRVINE, Calif., January 15, 2026--Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care",
    "url": "https://finnhub.io/api/news?id=0f9647da3f0e914d46151f8d465bd73a62fc3e099a5b363fd2a567669995ef7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768489200,
      "headline": "Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer",
      "id": 138121855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "IRVINE, Calif., January 15, 2026--Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care",
      "url": "https://finnhub.io/api/news?id=0f9647da3f0e914d46151f8d465bd73a62fc3e099a5b363fd2a567669995ef7e"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Sell HSIC and 1 Stock to Buy Instead",
    "summary": "Henry Schein trades at $76.27 per share and has stayed right on track with the overall market, gaining 8% over the last six months. At the same time, the S&P 500 has returned 11.5%.",
    "url": "https://finnhub.io/api/news?id=d06087c7bf3b0ca3ca2ce4cd2759f3540190dfd744fc63d686920d05baae7759",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768449980,
      "headline": "3 Reasons to Sell HSIC and 1 Stock to Buy Instead",
      "id": 138121856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "Henry Schein trades at $76.27 per share and has stayed right on track with the overall market, gaining 8% over the last six months. At the same time, the S&P 500 has returned 11.5%.",
      "url": "https://finnhub.io/api/news?id=d06087c7bf3b0ca3ca2ce4cd2759f3540190dfd744fc63d686920d05baae7759"
    }
  }
]